• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Open Label Extension

When a clinical trial ends, participants typically stop taking the study drug until it receives approval from their country’s regulatory agency. If participants are benefiting from the drug and would have no other treatment options without it, they may be allowed to continue taking it as part of an open-label extension (OLE). In an OLE, all participants receive the study drug and know they are receiving it. Only people who have completed the initial portion of the study can take part in an OLE.

OLEs often follow phase 3 trials, the last phase before regulatory approval. They also commonly follow phase 1 or phase 2 trials of ALS/MND treatments. Many organizations strongly advocate for including some form of OLE in all industry-supported clinical trials.

OLEs are an act of compassion for people living with serious illnesses such as ALS/MND who take part in clinical trials. ALS/MND is a severe disease, and people who volunteer for clinical trials make a sacrifice, knowing they may receive a placebo. For this reason, everyone who participates should have access to an OLE that could maximize the potential benefit of the treatment, should it ultimately prove effective.

Scientific gain

An OLE benefits trial participants directly. A well-designed OLE can also provide useful data about the therapy that could benefit more people. OLEs often extend a trial by several months, allowing researchers to collect more information on the long-term efficacy, tolerability, and safety of the drug.

However, the validity of this data is limited because participants know they are receiving the treatment. This may create a placebo effect, which makes the drug’s benefit appear greater only because participants believe it should work.

The Alliance position

The Alliance believes that open-label extension studies must be incorporated into all clinical trial designs and protocols. This ensures that people living with ALS/MND can continue to access experimental therapies once their participation in a clinical trial has ended.

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • Mike Small, UK

    Mike Small, UK

  • Angela Jansen, Germany

    Angela Jansen, Germany

  • Angie Bordaen, Belgium

    Angie Bordaen, Belgium

  • Len Johnrose, England

    Len Johnrose, England

  • Ada Garrido Benavidez, Mexico

    Ada Garrido Benavidez, Mexico

  • Hiroshi Matsuyama, Japan

    Hiroshi Matsuyama, Japan

  • Barry de Reuver, Netherlands

    Barry de Reuver, Netherlands

  • Chen Yin Xue, Taiwan

    Chen Yin Xue, Taiwan

  • Mark Miller, UK

    Mark Miller, UK

  • Osiel Mendoza, USA

    Osiel Mendoza, USA

  • Chih Ching Darren Wong, Malaysia

    Chih Ching Darren Wong, Malaysia

  • Claudette Sturk, Canada

    Claudette Sturk, Canada
    Picture2

  • Danny Reviers, Belgium

    Danny Reviers, Belgium
    DannyReviers

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • John Russo, USA

    John Russo, USA
    final3878

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Joy Blakeley, Australia

    Joy Blakeley, Australia

  • Susan Anderson, USA

    Susan Anderson, USA

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Elkin Ramiro Gaviria Muñoz, Colombia

    Elkin Ramiro Gaviria Muñoz, Colombia

  • Mary Thomas, Australia

    Mary Thomas, Australia

  • Carlos Alberto Báez Murillo, Colombia

    Carlos Alberto Báez Murillo, Colombia

  • Steve Lufkin, USA

    Steve Lufkin, USA
    IMG_3993

  • Steve Gallagher, Canada

    Steve Gallagher, Canada
    Picture1

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Motoko Ogasawara, Japan

    Motoko Ogasawara, Japan

  • Marcel R. Wernard, Netherlands

    Marcel R. Wernard, Netherlands

  • Mikey Stone, ALS

    Mikey Stone, ALS

  • Greg Heydet, USA

    Greg Heydet, USA

  • Teddy Hanono Annie, Mexico

    Teddy Hanono Annie, Mexico

  • Dorette Lüdi, Switzerland

    Dorette Lüdi, Switzerland

  • Kirsty Gerlach, New Zealand

    Kirsty Gerlach, New Zealand

  • Charlie Dourney, USA

    Charlie Dourney, USA

  • Wendy Hendrickson, USA

    Wendy Hendrickson, USA

  • Lineke Veenstra, Netherlands

    Lineke Veenstra, Netherlands

  • Susan Keldani, USA

    Susan Keldani, USA

  • Dr. Janmejay Pradhan, India

    Dr. Janmejay Pradhan, India

  • Eric Von Schaumburg, USA

    Eric Von Schaumburg, USA

  • Jason Goodman, USA

    Jason Goodman, USA

  • David Hall, USA

    David Hall, USA

  • Ismail Gokcek, Turkey

    Ismail Gokcek, Turkey
    ismail_gokcek_alsmnd_tr

  • Lee Millard, England

    Lee Millard, England

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Calum Ferguson, Scotland

    Calum Ferguson, Scotland

  • Conny van der Meijden, Netherlands

    Conny van der Meijden, Netherlands

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • Roy Taylor, Ireland

    Roy Taylor, Ireland
    roy

  • David Watson, Scotland

    David Watson, Scotland

  • Rosie Riley, USA

    Rosie Riley, USA

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login